deferasirox has been researched along with Lymphoma, Large B-Cell, Diffuse in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, CW; Jeon, MJ; Kim, DS; Yu, ES | 1 |
| Bazargan, A; Chai, KL; Kostos, L; Tam, CS | 1 |
2 other study(ies) available for deferasirox and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
Topics: Antibodies, Monoclonal, Murine-Derived; Apoptosis; Cell Line, Tumor; Deferasirox; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Lymphoma, Large B-Cell, Diffuse; Mitogen-Activated Protein Kinase 13; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Rituximab | 2023 |
The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.
Topics: Aged; Benzoates; Bone Marrow; Deferasirox; Erythropoiesis; Female; Humans; Image-Guided Biopsy; Immunohistochemistry; Iron Chelating Agents; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Positron-Emission Tomography; Primary Myelofibrosis; Triazoles | 2017 |